143 related articles for article (PubMed ID: 37458549)
1. [Diagnosis and staging of Hodgkin lymphoma].
Ghesquières H
Rev Prat; 2023 Jun; 73(6):617-620. PubMed ID: 37458549
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin lymphoma.
Gobbi PG; Ferreri AJ; Ponzoni M; Levis A
Crit Rev Oncol Hematol; 2013 Feb; 85(2):216-37. PubMed ID: 22867814
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2016 Jun; 91(4):434-42. PubMed ID: 27001163
[TBL] [Abstract][Full Text] [Related]
4. Progress in the initial management of Hodgkin's Lymphoma.
Marri PR; Ansell SM
Transfus Apher Sci; 2013 Aug; 49(1):12-8. PubMed ID: 23769695
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2020 Aug; 95(8):978-989. PubMed ID: 32384177
[TBL] [Abstract][Full Text] [Related]
6. Management of Hodgkin lymphoma.
Ansell SM; Armitage JO
Mayo Clin Proc; 2006 Mar; 81(3):419-26. PubMed ID: 16529147
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2018 May; 93(5):704-715. PubMed ID: 29634090
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2014 Jul; 89(7):771-9. PubMed ID: 24953862
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity.
de Jong D; Bosq J; MacLennan KA; Diebold J; Audouin J; Chasle J; Mandard AM; Marnay J; Henry-Amar M; ;
Ann Oncol; 2006 Jan; 17(1):141-5. PubMed ID: 16284059
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma, version 2.2015.
Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Aoun P; Bello CM; Benitez CM; Bierman PJ; Blum KA; Chen R; Dabaja B; Forero A; Gordon LI; Hernandez-Ilizaliturri FJ; Hochberg EP; Huang J; Johnston PB; Khan N; Maloney DG; Mauch PM; Metzger M; Moore JO; Morgan D; Moskowitz CH; Mulroney C; Poppe M; Rabinovitch R; Seropian S; Tsien C; Winter JN; Yahalom J; Burns JL; Sundar H;
J Natl Compr Canc Netw; 2015 May; 13(5):554-86. PubMed ID: 25964641
[TBL] [Abstract][Full Text] [Related]
12. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.
Grellier JF; Vercellino L; Leblanc T; Merlet P; Thieblemont C; Weinmann P; Toubert ME; Berenger N; Brière J; Brice P
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2023-30. PubMed ID: 24965842
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2022 Nov; 97(11):1478-1488. PubMed ID: 36215668
[TBL] [Abstract][Full Text] [Related]
14. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma.
Agbay RLMC; Loghavi S; Zuo Z; Fayad L; Dabaja B; Medeiros LJ; Khoury JD
Am J Surg Pathol; 2018 Apr; 42(4):492-499. PubMed ID: 29309302
[TBL] [Abstract][Full Text] [Related]
16. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
Eichenauer DA; Hartmann S
Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
[TBL] [Abstract][Full Text] [Related]
18. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2012 Dec; 87(12):1096-103. PubMed ID: 23151980
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc; 2015 Nov; 90(11):1574-83. PubMed ID: 26541251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
